The Price of a Blockbuster, Renegotiated

A White House deal cut GLP-1 prices, opened Medicare to obesity drugs for the first time, and launched a government storefront. The economics of the year’s biggest drug category just reset.

On November 6, 2025, the administration announced agreements with Eli Lilly and Novo Nordisk that rewrote the economics of the two highest-spending drug franchises in the country. For a market defined by sticker shock — list prices around $1,000 to $1,350 a month — the deal changed the arithmetic. GLP-1 pricing is the through-line of the story.

The headline numbers

Under the agreements, Medicare and Medicaid will pay $245 a month for Ozempic, Wegovy, Mounjaro, and Zepbound across doses and indications. For the first time, Medicare will cover Wegovy and Zepbound for obesity itself — not only for diabetes or heart risk — with beneficiaries facing a $50 copay.

Cash-paying patients gain a new route: TrumpRx, a government-branded storefront, with prices averaging near $350 a month at launch and trending toward $245 over roughly two years. Future oral GLP-1 drugs would start around $150 a month. Insulin was capped at $35.

What the companies got in return

Deals like this are trades. In exchange for the price concessions, Lilly and Novo secured a three-year reprieve from pharmaceutical tariffs and committed to large domestic manufacturing investments — Lilly pledging at least $27 billion, Novo around $10 billion in U.S. capacity.

The pricing pairs with a most-favored-nation principle: the companies agreed to launch new drugs in the U.S. at prices no higher than what comparable wealthy nations pay. That idea — that Americans should not pay multiples of the European price for the same molecule — has circulated for years. These agreements attempt to operationalize it for the highest-profile drug class in the market.

The mechanics are still being built.

The framework is clearer than the plumbing. TrumpRx is expected to go live in 2026, and the expanded Medicare obesity coverage phases in over the following period rather than switching on overnight. Exactly how the cash-pay discounts, the government storefront, and existing insurance coverage interact is still being wired together, and the details will shape how much any individual actually pays.

Skeptics note the gaps. A $245 government-and-Medicare price is transformative for some, but people with commercial insurance, high deductibles, or no coverage may see a different figure. And a voluntary deal between an administration and two companies is not the same as a statute; its durability depends on political and commercial winds.

Why it matters

For a category where affordability, not efficacy, is the binding constraint, price is the story. Surveys have consistently shown large numbers of patients rationing or abandoning GLP-1 drugs over cost. Medicare’s first-ever coverage of anti-obesity medication is a structural change, extending access to a population — older adults — with high obesity-related disease burden and, until now, an explicit statutory exclusion for weight-loss drugs.

What it means

The deal does not make GLP-1 drugs cheap in absolute terms, and its benefits arrive unevenly across insurance situations. What it does is bend a curve that had put these medicines out of reach for millions, while binding the manufacturers to U.S. production and to a pricing principle that could outlast this particular arrangement.

For patients, the practical advice is to watch the rollout closely: confirm how TrumpRx pricing, Medicare coverage, and any commercial plan stack for your specific situation, because the same drug may now carry very different prices depending on how you buy it.

Frequently asked questions

How much do GLP-1 drugs cost under the deal? Medicare and Medicaid will pay $245 a month for Ozempic, Wegovy, Mounjaro, and Zepbound. Cash prices through the new TrumpRx storefront start near $350 and trend toward $245 over about two years, with future oral GLP-1 drugs around $150.

Does Medicare cover Wegovy now? For the first time, yes — the deal opens Medicare coverage of Wegovy and Zepbound for obesity itself, not only for diabetes or heart risk, with a $50 copay. Coverage phases in rather than switching on overnight.

What is TrumpRx? A government-branded storefront where cash-paying patients can buy these medicines at negotiated discounts. It is expected to go live in 2026, and exactly how it stacks with insurance and Medicare is still being wired together.

Sources

1. The White House — fact sheet on agreements with Eli Lilly and Novo Nordisk on GLP-1 pricing and TrumpRx, November 6, 2025.
2. Eli Lilly and Company and Novo Nordisk A/S — statements on the pricing agreements and U.S. investment commitments, November 2025.
3. CNBC, STAT, and NPR — reporting on the GLP-1 pricing deal and Medicare coverage, November 6–7, 2025.
4. Centers for Medicare & Medicaid Services (CMS) — materials on Medicare coverage of anti-obesity medications, 2025–2026.